EphemerisX Research · Deep research
Cross-investigations whose records belong together as a divergent outcome. How this research works →
AllComparable evidenceDivergent outcomeRegulatory pathwayShared concern
Five companies, five paths. Replimune and CorMedix were approved after one more resubmission; Verrica after a third letter; Outlook's appeal after a third letter was granted and it resubmitted; Aldeyra, after a third letter, plans to appeal.
Aldeyra Therapeutics · CorMedix · Outlook Therapeutics · Replimune · Verrica PharmaceuticalsRead →
Prepared from public FDA letters and SEC filings: every quoted passage is matched to the original document, and every “not in” statement comes from a search of the whole document, before it is published. Questions, summaries and connecting sentences are EphemerisX’s wording. Not investment advice. How this research works → · Ask the FDA and SEC Ephemeris →
